Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search

Invention Type

Information Technology/Software
Medical Device
Research Tool

Research Area

Allergy/Respiratory/Pulmonary Disease
Degenerative Disease
Genetic Disease
Health Care Management
Infectious Disease
Internal Medicine
Metabolic Disease
Personalized Medicine
Psychiatric Disease
Regenerative Medicine
Stem Cell
Surgery/Wound Healing
CMCC 600

Administration of inosine to stimulate innervation and recovery of motor function

Inventors: Larry Benowitz, David Goldberg

Invention Types: Therapeutics

Research Areas: Neurology/Neuroscience, Surgery/Wound Healing

Keywords: Spinal Cord Injury, Stroke

Related Cases: 1183, 1709

For More Information Contact:  Caron, Connie


Invention Description:

There are an estimated 10,000 to 12,000 spinal cord injuries every year in the United States. A quarter of a million Americans are currently living with spinal cord injuries. The cost of managing the care of spinal cord injury patients approaches $4 billion each year. (Facts and Figures at a Glance, May 2001. National Spinal Cord Injury Statistical Center)

According to the America Heart Association, among adults age 20 and older, the prevalence of stroke in 2005 was 6.5 million and each year about 795,000 people experience a new or recurrent stroke. About 600,000 of these are first attacks, and 185,000 are recurrent attacks.

The inventors have found that inosine, a naturally occurring substance, could improve outcomes following injury by stimulating reinnervation of damaged brain regions. |

Inosine could be used alone or in combination with other trophic factors, such as mannose or oncomodulin, or in combination with inhibitors of pathways that block axon growth.

Additional cases in this portfolio:

CMCC 924: Inventors Larry Benowitz and Nina Irwin

CMCC 1154: Inventors Larry Benowitz and Dietmar Fischer

CMCC 1709: Inventor Nina Irwin


Use of inosine and other molecules that would modulates inosine's target (Mst3b) in combination with inhibitors of pathways that block axon growth such as Nogo Receptor (NgR) inhibitor to treat:

• Spinal Cord Injury

• Stroke

• Possibly neurodegenerative diseases or conditions

Competitive Advantages:

• There is no treatment for spinal cord injuries.

• Inosine is known to be safe: it is now in clinical trials for other indications such as Parkinson's disease and may have applications in other types of neurological damage.

• Inosine is known to cross the blood-brain barrier suggesting that delivery could be straight forward.

Business Opportunity:

Available for exclusive or non-exclusive license |

Opportunity for sponsored research and co-development

• Analogs and formulations of inosine

• Preclinical studies on therapeutic window and optimizing conditions for delivery

• Clinical trials for enhancing brain plasticity after stroke

• Clinical trials for improved outcomes after stroke, SCI and other neurological conditions

Key Publications: Benowitz LI, Carmichael ST. Promoting axonal rewiring to improve outcome after stroke. Neurobiol Dis. 2010 Feb;37(2):259-66. Epub 2009 Nov 26. PMID: 19931616 || Zai L, Ferrari C, Subbaiah S, Havton LA, Coppola G, Strittmatter S, Irwin N, Geschwind D, Benowitz LI. Inosine alters gene expression and axonal projections in neurons contralateral to a cortical infarct and improves skilled use of the impaired limb. J Neurosci. 2009 Jun 24;29(25):8187-97. PMID: 19553458 || Irwin N, Li YM, O'Toole JE, Benowitz LI. Mst3b, a purine-sensitive Ste20-like protein kinase, regulates axon outgrowth. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18320-5. Epub 2006 Nov 17. PMID: 17114295

IPStatus: Pat. Pend.